首页> 外文期刊>American Journal of Transplantation >Time Trends in Risk and Risk Determinants of Non-Hodgkin Lymphoma in Solid Organ Transplant Recipients
【24h】

Time Trends in Risk and Risk Determinants of Non-Hodgkin Lymphoma in Solid Organ Transplant Recipients

机译:固体器官移植受者中非霍奇金淋巴瘤的风险和风险决定因素的时间趋势

获取原文
获取原文并翻译 | 示例
           

摘要

Organ transplantation increases risk of non-Hodgkin lymphoma (NHL), but long-term risk and time trends have seldom been evaluated. Immunosuppressive drug load is an important risk determinant, but the details are unclear. We studied NHL risk in a nationwide Swedish cohort of 11 081 graft recipients transplanted 1970–2008. Relative risks (RRs) were estimated within the cohort and versus the general population by age, sex, follow-up time and calendar period. NHL risk was also assessed by cumulative and average doses of immunosuppressive treatments in a nested case-control design throughout 1997 using conditional logistic regression. We observed 153 NHL cases during 97 853 years of follow-up. Compared with the general population, NHL risk was eightfold increased (RR 7.9; 95% confidence interval [CI] 6.6–9.4), and increased risks persisted after ≥15 years of follow-up among kidney (6.1; 95% CI 3.5–10) and nonkidney recipients (44; 14–103). Among nonkidney recipients, NHL risk was lower in the 2000s compared with the 1990s (0.5; 95% CI 0.3–1.0; p = 0.04). A high average dose of antithymocyte immunoglobulin (ATG) conferred an eightfold increased risk of NHL (OR 8.5; 95% CI 1.9–38). To conclude, posttransplant NHL risk decreased during the last decade among nonkidney recipients, possibly because of a more careful use of ATG, the introduction of new drugs, or both.
机译:器官移植会增加非霍奇金淋巴瘤(NHL)的风险,但很少评估长期风险和时间趋势。免疫抑制药物负荷是重要的风险决定因素,但细节尚不清楚。我们在瑞典全国范围内的1970-2008年移植的11 081个移植受者中研究了NHL风险。根据年龄,性别,随访时间和日历期,评估了同龄人中相对于一般人群的相对风险(RRs)。在整个1997年的巢式病例对照设计中,使用条件逻辑回归,还通过免疫抑制治疗的累积剂量和平均剂量来评估NHL风险。在97 853年的随访期间,我们观察到153例NHL病例。与普通人群相比,NHL风险增加了八倍(RR 7.9; 95%置信区间[CI] 6.6–9.4),并且在≥15年的肾脏随访中,风险增加持续存在(6.1; 95%CI 3.5-10 )和非肾脏患者(44; 14–103)。在非肾脏接受者中,与1990年代相比,2000年代的NHL风险较低(0.5; 95%CI 0.3-1.0; p = 0.04)。高平均剂量的抗胸腺细胞免疫球蛋白(ATG)使NHL的风险增加了八倍(OR 8.5; 95%CI 1.9-38)。总而言之,在过去十年中,非肾移植患者的移植后NHL风险降低了,这可能是因为更谨慎地使用ATG,引入新药或两者兼而有之。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号